IRVINE, Calif., July 15, 2020 /PRNewswire/ -- Edwards
Lifesciences Corporation (NYSE: EW), the global leader in
patient-focused innovations for structural heart disease and
critical care monitoring, today announced that Paul A. LaViolette has been appointed to its
board of directors. LaViolette has 40 years of experience in global
medical technology, operating leadership and investing, serving in
executive-level roles at companies including Boston Scientific
Corp. and C.R. Bard Inc.
LaViolette is currently managing partner and chief operating
officer of SV Health Investors LLC, a specialist healthcare fund
management company. He also oversees its medical device
investments.
"Paul is a highly respected and talented leader within the
medical technology industry, and his experience working with both
large, global organizations and start-ups provides him with a
unique perspective on strategy and innovation," said Michael A. Mussallem, Edwards' chairman and CEO.
"We are very pleased to welcome Paul to Edwards' board, and we are
confident that his breadth of experience within companies and on
boards will enable him to be an immediate contributor, offering
valuable insight to Edwards."
Edwards announced in May the appointment of Ramona Sequeira to the board, and that
Martha Marsh, a board member since
2015, would assume the role of lead independent director.
With the appointment of LaViolette, Edwards' board increases to
nine directors.
About Edwards Lifesciences
Edwards Lifesciences, based in Irvine, Calif., is the
global leader of patient-focused medical innovations for structural
heart disease and critical care monitoring. We are driven by a
passion for patients, dedicated to improving and enhancing lives
through partnerships with clinicians and stakeholders across the
global healthcare landscape. For more information, visit
Edwards.com and follow us on Facebook, Instagram, LinkedIn, Twitter
and YouTube.
This news release includes forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933 and Section
21E of the Securities Exchange Act of 1934. These forward-looking
statements include, but are not limited to, the statement made
by Michael Mussallem.
Forward-looking statements are based on estimates and assumptions
made by management of the company and are believed to be
reasonable, though they are inherently uncertain and difficult to
predict. Our forward-looking statements speak only as of the date
on which they are made and we do not undertake any obligation to
update any forward-looking statement to reflect events or
circumstances after the date of the statement. Statements of
past performance, efforts, or results about which inferences or
assumptions may be made can also be forward-looking statements and
are not indicative of future performance or results; these
statements can be identified by the use of words such as
"continued," "transform," "develop," "preliminary," "initial,"
diligence," "industry-leading," "compliant," "indications," or
"early feedback" or other forms of these words or similar words or
expressions or the negative thereof. Investors are cautioned
not to unduly rely on such forward-looking statements.
Forward-looking statements involve risks and uncertainties that
could cause results to differ materially from those expressed or
implied by the forward-looking statements based on a number of
factors as detailed in the company's filings with the Securities
and Exchange Commission including its Annual Report on Form 10-K
for the year ended December 31, 2019
and the Quarterly Report on Form 10-Q for the quarter ended
March 31, 2020. These filings, along
with important safety information about our products, may be found
at edwards.com.
Edwards, Edwards Lifesciences and the stylized E logo are
trademarks of Edwards Lifesciences Corporation. All other
trademarks are the property of their respective owners. This
statement is made on behalf of Edwards Lifesciences Corporation and
its subsidiaries.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/paul-laviolette-appointed-to-edwards-lifesciences-board-of-directors-301093402.html
SOURCE Edwards Lifesciences Corporation